Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published August 2011
  • Article
  • Info & Metrics
  • PDF
Loading

Preclinical Profile of Dual mTORC1/2 Inhibitor OSI-027

Bhagwat et al., Page 1394

The PI3K/AKT/mTOR pathway is frequently activated in human cancers and mTOR is a central regulator of this pathway. To inhibit both mTORC1 and mTORC2 activity, Bhagwat and colleagues have discovered OSI-027, a selective, small molecule ATP competitive inhibitor that is mechanistically and functionally distinct from rapamycin.OSI-027 showed significant mechanistic inhibition of mTORC1 and mTORC2 and broad-spectrum tumor growth inhibition in several xenograft models including those harboring PTEN deficiencies/mutations and PIK3CA mutations. The breadth of these results indicate a global effect of mTOR signaling pathways and a potential to treat a variety of human cancers that may not be as responsive to rapalogs.

Combined PI3K/mTOR and MEK Inhibition in Ovarian Cancer

Kinross et al., Page 1440

Ovarian cancers commonly exhibit upregulation of the PI3K/mTOR signaling. Using a genetically engineered ovarian cancer mouse model (Pten deletion;KrasG12D),Kinross and colleagues show that PF-04691502, a PI3K and mTOR inhibitor in clinical development, potently inhibits PI3K/mTOR signaling, FDG-PET activity, and inhibits tumor growth in vivo. However, PF-04691502 exhibited only short-term benefit as a single agent.Long-term therapeutic benefit could be achieved through combined therapy of PF-04691502 with MEK inhibitor PD-0325901, which, via coordinated activation of apoptosis, led to tumor regression. This study identifies combination PF-04691502 and PD-0325901 therapy as a promising new approach for the treatment of ovarian cancers.

Combined Treatment in Triple-Negative Breast Cells

Liu et al., Page 1460

Triple-negative breast cancers have the worst prognosis of any subset of breast cancer, at least in part because of a lack of viable therapeutic targets.Epidermal growth factor receptor (EGFR) is overexpressed in approximately 50% of triple-negative breast cancers, but attempts at targeting this receptor in clinical trials have, to date, produced disappointing results. Liu and colleagues show that mTOR inhibition in combination with EGFR inhibition leads to synergistic effects in triple-negative breast cancers in vitro and suppressed tumor growth in vivo. They are currently evaluating the combination of the EGFR inhibitor, lapatinib, and the mTOR inhibitor, everolimus, in patients with metastatic triplenegative breast cancer.

Systemic MicroRNA Delivery Using Nanovectors

Pramanik et al., Page 1470

Misexpression of microRNAs (miRNA) is widespread in human cancers, with aberrations including overexpression of oncogenic miRs and downregulation of tumor suppressor miRs (TSG-miR). Pramanik and colleagues developed a method of restituting expression of downregulated TSG-miRs in vivo using a lipid-based nanoparticle for systemic delivery of miRNA expression vectors (nanovector).Selecting two candidate TSG-miRs (miR-34a and the miR-143/145 cluster), the authors show the usefulness of the nanovector platform—one with potential broad applicability in systemic miRNA delivery to cancer cells—in both subcutaneous and orthotopic xenograft models of pancreatic cancer.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (8)
August 2011
Volume 10, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther August 1 2011 (10) (8) 1309;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther August 1 2011 (10) (8) 1309;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Preclinical Profile of Dual mTORC1/2 Inhibitor OSI-027
    • Combined PI3K/mTOR and MEK Inhibition in Ovarian Cancer
    • Combined Treatment in Triple-Negative Breast Cells
    • Systemic MicroRNA Delivery Using Nanovectors
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement